Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:02 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Vedolizumab Post Op Study
NCT02834754 · Marc Schwartz · PHASE2 · withdrawn · last registry update 2020-05-14 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Limited time for enrollment of required number of subjects” | – | Registry record, Marc Schwartz |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ITGA4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-05-06Also stopped (withdrawn): Eli Lilly and Company, Mirikizumab IV + Mirikizumab SC (NCT04469062)
- 2021-04-27Results posted on the registry: Biogen, Natalizumab (NCT03283371)
- 2021-04-01Results posted on the registry: Millennium Pharmaceuticals, Inc., TAK-580 + TAK-202 (NCT02723006)
- 2021-03-03Phase 3 first posted: Takeda, Vedolizumab IV (NCT04779320)
- 2021-03-03Phase 3 first posted: Takeda, Vedolizumab (NCT04779307)
- 2021-02-04Phase 3 first posted: Takeda, Vedolizumab (NCT04738942)
- 2020-12-21Results posted on the registry: Takeda, Vedolizumab (NCT03138655)
- 2020-10-27Also stopped (withdrawn): Takeda, Caffeine + Losartan (NCT02760615)
- 2020-09-03Results posted on the registry: Medical College of Wisconsin, Tacrolimus + Vedolizumab (NCT02954159)
- 2020-09-03Also stopped (terminated): Medical College of Wisconsin, Tacrolimus + Vedolizumab (NCT02954159)
- 2020-08-12Results posted on the registry: Northwestern University, Standard treatment with a conventional drug (NCT00273364)
- 2020-07-13Phase 3 first posted: Eli Lilly and Company, Mirikizumab IV + Mirikizumab SC (NCT04469062)
- 2020-06-23Results posted on the registry: Takeda, Vedolizumab SC 108 mg + Placebo (NCT02611817)
- 2020-04-17Results posted on the registry: Dana-Farber Cancer Institute, Natalizumab + Methylprednisolone (NCT02176031)
- 2020-03-04Results posted on the registry: Takeda, Vedolizumab (NCT02559713)
- 2020-01-23Results posted on the registry: Takeda, Vedolizumab 300 mg IV + Placebo IV (NCT02611830)
- 2019-12-16Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), Entyvio (Vedolizumab) (NCT02788175)
- 2019-12-09Results posted on the registry: Takeda, Vedolizumab + Vedolizumab placebo (NCT02038920)
- 2019-11-18Results posted on the registry: Takeda, Vedolizumab SC (NCT03948581)
- 2019-10-10Results posted on the registry: Takeda, Vedolizumab + Adalimumab placebo (NCT02497469)
- 2019-10-04Phase 3 first posted: Polpharma Biologics S.A., Intravenous (IV) infusions (NCT04115488)
- 2019-09-27Also stopped (terminated): Biogen, Daclizumab (NCT02881567)
- 2019-09-25Results posted on the registry: Takeda, Vedolizumab + Placebo (NCT02630966)
- 2019-09-24Results posted on the registry: Biogen, Daclizumab (NCT02881567)
- 2019-09-23Results posted on the registry: Takeda, Vedolizumab SC (NCT03961308)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision